Investigational drug · Phase 2
AGLE-102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dystrophic Epidermolysis Bullosa.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "AGLE-102"
First trial start
2024
Aug 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AGLE-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dystrophic Epidermolysis Bullosa
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "AGLE-102" as an intervention, largest first.
Aegle TherapeuticsIndustry
NCT04173650 · 8 participants (planned) · Start Aug 13, 2024 · Primary completion Sep 2025
Drug: AGLE-102 · For: Dystrophic Epidermolysis Bullosa
Sites: Phoenix, Arizona; Los Angeles, California; Philadelphia, Pennsylvania
Aegle TherapeuticsIndustry
NCT05078385 · 1 participants · Start Aug 10, 2023 · Primary completion Sep 5, 2024
Drug: AGLE-102 · For: Burns
Sites: Miami, Florida; Chapel Hill, North Carolina
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Dystrophic Epidermolysis Bullosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.